Company: ABBV
Filing Date: 2025-02-20
Form Type: 424B5
Source: 0001104659-25-015715
Chunk: 9

Company: AbbVie Inc.
Filing Date: 2025-02-20
Form: 424B5
Chunk 9
---
 should carefully consider the following risk factors, as well as the other information included or incorporated by reference into this prospectus supplement and the accompanying prospectus, before making an investment decision. These risks are not the only risks that we face in our business and/or in connection with this offering. Our business, financial condition and results of operations and/or the Notes offered hereby could also be affected by additional factors that are not presently known to us or that we currently do not consider to be material.

### Risks Relating to Our Business
For a discussion of the risks related to our business you should carefully consider the risks, uncertainties and assumptions discussed under “Part I — Item 1A. Risk Factors” in the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other documents that we subsequently file with the SEC that update, supplement or supersede such information, all of which are incorporated by reference into this prospectus supplement. See “ Where to Obtain More Information .”

#### Risks Related to this Offering
In addition to indebtedness that will be issued in this offering, the Issuer has significant outstanding unused borrowing capacity and significant outstanding debt and may incur additional debt in the future. The terms of such indebtedness could restrict the activities of AbbVie.

As of December 31, 2024, AbbVie had $64.8 billion aggregate principal amount (calculated based on exchange rates in effect as of December 31, 2024) of outstanding unsecured senior notes (the “ Existing Notes ”), including $15.0 billion aggregate principal amount of unsecured senior notes issued in February 2024. The Existing Notes are unsecured, unsubordinated obligations of the Issuer and rank equally in right of payment with all of the Issuer’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. The Issuer may redeem the Existing Notes prior to maturity at redemption prices specified therein, in accordance with their respective terms.

The Issuer entered into a new $3.0 billion five-year revolving credit facility (the “ 2030 Revolving Credit Facility ”) with various financial institutions in January 2025 and an amended and restated $5.0 billion five-year revolving credit facility (the “ 2028 Revolving Credit Facility ” and, together with the 2030 Revolving Credit Facility, the “ Revolving Credit Facilities ”) with various financial institutions in March 2023. In October 2024, the Issuer